Amneal Pharmaceuticals
AMRX
167 hedge funds and large institutions have $2.41B invested in Amneal Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 36 funds opening new positions, 57 increasing their positions, 48 reducing their positions, and 34 closing their positions.
61.77% more ownership
Funds ownership: 32.68% → 94.44% (+62%)
51% more capital invested
Capital invested by funds: $1.6B → $2.41B (+$808M)
20% more call options, than puts
Call options by funds: $1.47M | Put options by funds: $1.22M
19% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 48
1% more funds holding
Funds holding: 165 → 167 (+2)
6% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 34
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$232M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$44.1M |
| 3 |
Janus Henderson Group
London,
|
+$42.2M |
| 4 |
Viking Global Investors
Stamford,
Connecticut
|
+$32.4M |
| 5 |
HM
HealthCor Management
New York
|
+$21.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MC
Maverick Capital
Dallas,
Texas
|
-$45.7M |
| 2 |
Millennium Management
New York
|
-$32.7M |
| 3 |
Fisher Asset Management
Camas,
Washington
|
-$24M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$23.3M |
| 5 |
FI
Fosun International
Hong Kong,
China
|
-$15.6M |
AMRX Hedge Fund Activity: Q3 2018 in Review
167 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Amneal Pharmaceuticals (AMRX) for Q3 2018, worth a combined $2.41B — up 51% from $1.6B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new AMRX positions and 34 closed out — a net gain of 2 holders — while 57 added to existing stakes and 48 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $232M. The largest seller was Maverick Capital, exiting entirely with an estimated $45.7M sold.
- 167 institutional investors held Amneal Pharmaceuticals (AMRX) as of Q3 2018, up from 165 in Q2 2018.
- Funds reported $2.41B of Amneal Pharmaceuticals stock for Q3 2018, up 51% quarter-over-quarter.
- 36 funds opened new Amneal Pharmaceuticals positions in Q3 2018 and 34 closed out, a net change of +2 holders.
- The largest Amneal Pharmaceuticals buyer in Q3 2018 was T. Rowe Price Associates, an estimated $232M added.
- The largest Amneal Pharmaceuticals seller in Q3 2018 was Maverick Capital, an estimated $45.7M sold.
Based on aggregated 13F filings for Q3 2018.